) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of asthma in patients aged 18 years ...
Last month, GlaxoSmithKline ($GSK) CEO Andrew Witty told reporters that its new, slow-starter lung drugs were finally picking up steam. That's something the company ...
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results